These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 24129244)

  • 1. ALK gene amplification is associated with poor prognosis in colorectal carcinoma.
    Bavi P; Jehan Z; Bu R; Prabhakaran S; Al-Sanea N; Al-Dayel F; Al-Assiri M; Al-Halouly T; Sairafi R; Uddin S; Al-Kuraya KS
    Br J Cancer; 2013 Nov; 109(10):2735-43. PubMed ID: 24129244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK gene copy number gain and its clinical significance in hepatocellular carcinoma.
    Jia SW; Fu S; Wang F; Shao Q; Huang HB; Shao JY
    World J Gastroenterol; 2014 Jan; 20(1):183-92. PubMed ID: 24415871
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.
    Lee J; Kim HC; Hong JY; Wang K; Kim SY; Jang J; Kim ST; Park JO; Lim HY; Kang WK; Park YS; Lee J; Lee WY; Park YA; Huh JW; Yun SH; Do IG; Kim SH; Balasubramanian S; Stephens PJ; Ross JS; Li GG; Hornby Z; Ali SM; Miller VA; Kim KM; Ou SH
    Oncotarget; 2015 Sep; 6(27):24320-32. PubMed ID: 26172300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALK Gene Copy Number Gain and Immunohistochemical Expression Status Using Three Antibodies in Neuroblastoma.
    Kim EK; Kim S
    Pediatr Dev Pathol; 2017; 20(2):133-141. PubMed ID: 28326957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations.
    Peretti U; Ferrara R; Pilotto S; Kinspergher S; Caccese M; Santo A; Brunelli M; Caliò A; Carbognin L; Sperduti I; Garassino M; Chilosi M; Scarpa A; Tortora G; Bria E
    Respir Res; 2016 Aug; 17(1):105. PubMed ID: 27561692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implication.
    Kim MH; Lee S; Koo JS; Jung KH; Park IH; Jeong J; Kim SI; Park S; Park HS; Park BW; Kim JH; Sohn J
    PLoS One; 2015; 10(3):e0120320. PubMed ID: 25803816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study.
    Lee JS; Lim SM; Rha SY; Roh JK; Cho YJ; Shin KH; Yang WI; Kim SH; Kim HS
    J Clin Pathol; 2014 Jan; 67(1):33-9. PubMed ID: 23922356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer.
    Salido M; Pijuan L; Martínez-Avilés L; Galván AB; Cañadas I; Rovira A; Zanui M; Martínez A; Longarón R; Sole F; Serrano S; Bellosillo B; Wynes MW; Albanell J; Hirsch FR; Arriola E
    J Thorac Oncol; 2011 Jan; 6(1):21-7. PubMed ID: 21107285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK alteration is a frequent event in aggressive breast cancers.
    Siraj AK; Beg S; Jehan Z; Prabhakaran S; Ahmed M; R Hussain A; Al-Dayel F; Tulbah A; Ajarim D; Al-Kuraya KS
    Breast Cancer Res; 2015 Sep; 17():127. PubMed ID: 26384210
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anaplastic lymphoma kinase status in rhabdomyosarcomas.
    Yoshida A; Shibata T; Wakai S; Ushiku T; Tsuta K; Fukayama M; Makimoto A; Furuta K; Tsuda H
    Mod Pathol; 2013 Jun; 26(6):772-81. PubMed ID: 23307059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of ALK gene alterations in urothelial carcinoma.
    Bellmunt J; Selvarajah S; Rodig S; Salido M; de Muga S; Costa I; Bellosillo B; Werner L; Mullane S; Fay AP; O'Brien R; Barretina J; Minoche AE; Signoretti S; Montagut C; Himmelbauer H; Berman DM; Kantoff P; Choueiri TK; Rosenberg JE
    PLoS One; 2014; 9(8):e103325. PubMed ID: 25083769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unproductive Effects of ALK Gene Amplification and Copy Number Gain in Non-Small-Cell Lung Cancer. ALK Gene Amplification and Copy Gain in NSCLC.
    Zito Marino F; Botti G; Aquino G; Ferrero S; Gaudioso G; Palleschi A; Rocco D; Salvi R; Micheli MC; Micheli P; Morabito A; Rocco G; Giordano A; De Cecio R; Franco R
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664698
    [No Abstract]   [Full Text] [Related]  

  • 13. Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene.
    Pelosi G; Gasparini P; Cavazza A; Rossi G; Graziano P; Barbareschi M; Perrone F; Barberis M; Takagi M; Kunimura T; Yamada T; Nakatani Y; Pastorino U; Scanagatta P; Sozzi G; Garassino M; De Braud F; Papotti M
    Lung Cancer; 2012 Sep; 77(3):507-14. PubMed ID: 22705117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALK alterations in adult renal cell carcinoma: frequency, clinicopathologic features and outcome in a large series of consecutively treated patients.
    Sukov WR; Hodge JC; Lohse CM; Akre MK; Leibovich BC; Thompson RH; Cheville JC
    Mod Pathol; 2012 Nov; 25(11):1516-25. PubMed ID: 22743654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new look at the ALK gene in cancer: copy number gain and amplification.
    Zito Marino F; Rocco G; Morabito A; Mignogna C; Intartaglia M; Liguori G; Botti G; Franco R
    Expert Rev Anticancer Ther; 2016 May; 16(5):493-502. PubMed ID: 26943457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic Activation upon MET and ALK Coamplification Sustains Targeted Therapy in Sarcomatoid Carcinoma, a Deadly Subtype of Lung Cancer.
    Pelosi G; Gasparini P; Conte D; Fabbri A; Perrone F; Tamborini E; Pupa SM; Ciravolo V; Caserini R; Rossi G; Cavazza A; Papotti M; Nakatani Y; Maisonneuve P; Pastorino U; Sozzi G
    J Thorac Oncol; 2016 May; 11(5):718-728. PubMed ID: 26804638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenic ALK Fusion in Rare and Aggressive Subtype of Colorectal Adenocarcinoma as a Potential Therapeutic Target.
    Yakirevich E; Resnick MB; Mangray S; Wheeler M; Jackson CL; Lombardo KA; Lee J; Kim KM; Gill AJ; Wang K; Gowen K; Sun J; Miller VA; Stephens PJ; Ali SM; Ross JS; Safran H
    Clin Cancer Res; 2016 Aug; 22(15):3831-40. PubMed ID: 26933125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status.
    Pietrantonio F; Maggi C; Di Bartolomeo M; Facciorusso MG; Perrone F; Testi A; Iacovelli R; Miceli R; Bossi I; Leone G; Milione M; Pelosi G; de Braud F
    PLoS One; 2014; 9(4):e92147. PubMed ID: 24691006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ALK amplification and protein expression predict inferior prognosis in neuroblastomas.
    Wang M; Zhou C; Sun Q; Cai R; Li Y; Wang D; Gong L
    Exp Mol Pathol; 2013 Oct; 95(2):124-30. PubMed ID: 23797004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.
    Paik JH; Choe G; Kim H; Choe JY; Lee HJ; Lee CT; Lee JS; Jheon S; Chung JH
    J Thorac Oncol; 2011 Mar; 6(3):466-72. PubMed ID: 21258247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.